Form 1

HRSA AIDS Drug Assistance Quarterly Report

0294 ADAP

HRSA AIDS Drug Assistance Quarterly Report

OMB: 0915-0294

Document [doc]
Download: doc | pdf

PowerPlusWaterMarkObject3

OMB No: 0915-0294

Expiration Date:






AIDS Drug Assistance Program

Quarterly Data Report
















HIV/AIDS Bureau

Division of Science and Policy

Health Resources and Services Administration

5600 Fishers Lane, Room 7-90

Rockville, MD 20857







PUBLIC BURDEN STATEMENT: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number. The OMB control number for this project is 0915-0294. Public reporting burden for this collection of information is estimated as 7.5 hours per respondent per year. These estimates include the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments to HRSA Reports Clearance Officer, Health Resources and Services Administration, Room 14-43, 5600 Fishers Lane, Rockville, MD. 20857.



COVER PAGE

All Ryan White Care Act grantees must complete this cover page if submitting a quarterly data report by paper


Grantee Contact Information

  1. Grantee name:


  1. Grant number:














  1. ADAP number:







  1. D-U-N-S number:







-







  1. Grantee address:

  1. Street:

  2. City: State:

  3. ZIP Code: __ __ __ __ __ - __ __ __ __


  1. Contact information for the ADAP Coordinator/Administrator:

  1. Name:

  2. Title:

  3. Phone #: (__ __ __) __ __ __ - __ __ __ __

  4. Fax #: (__ __ __) __ __ __ - __ __ __ __

  5. E-mail:


  1. Check the Report Quarter for which you are submitting data:

  • 1st (April 1 – June 30, report due July 31)

  • 2nd (July 1 – September 30, report due October 31)

  • 3rd (October 1 – December 31, report due January 31)

  • 4th (January 1 – March 31, report due April 30)


Section 1: Quarterly Submission


Section 1 (Items 1–12) should be completed for each quarter. Please review the Instructions for Completing the ADAP Quarterly Report to ensure that you respond to each item appropriately.


A. CLIENT UTILIZATION


  1. For the current reporting quarter (ending [June 30, 2005]), please indicate the UNDUPLICATED number of:

  1. Total clients enrolled in the ADAP at any time during the quarter

  2. NEW clients enrolled in the ADAP

  3. Clients who received at least one drug through the ADAP

  4. NEW clients who received at least one drug through the ADAP

  5. Clients who received any type of insurance service (premiums, co-pays, deductibles)

  6. NEW clients who received any type of insurance service (premiums, co-pays, deductibles)


  1. Gender distribution of total unduplicated ADAP clients:

Gender

(a)

Total Enrolled Clients

(b)

New Enrolled Clients

(c)

Total Clients Served*

(d)

New Clients Served*

(e)

Insurance Clients


(f)

New Insurance Clients

Males







Females







Transgender







Unknown/unreported







Total







*Served clients must have received at least one drug through the ADAP.


  1. Age distribution of total unduplicated ADAP clients:

Age

(a)

Total Enrolled Clients

(b)

New Enrolled Clients

(c)

Total Clients Served*

(d)

New Clients Served*

(e)

Insurance Clients


(f)

New Insurance Clients

Less than 2 years







2–12 years







13–24 years







25–44 years







45–64 years







65 years or older







Unknown/unreported







Total







*Served clients must have received at least one drug through the ADAP.

  1. Racial distribution for total unduplicated Hispanic/Latino ADAP clients:

Race

(a)

Total Enrolled Clients

(b)

New Enrolled Clients

(c)

Total Clients Served*

(d)

New Clients Served*

(e)

Insurance Clients


(f)

New Insurance Clients

White







Black or African American







Asian







Native Hawaiian or Other Pacific Islander







American Indian or Alaska Native







More than one race







Unreported







Total







*Served clients must have received at least one drug through the ADAP.


  1. Racial distribution for total unduplicated non-Hispanic/0Latino ADAP clients:

Race/Ethnicity

(a)

Total Enrolled Clients

(b)

New Enrolled Clients

(c)

Total Clients Served*

(d)

New Clients Served*

(e)

Insurance Clients


(f)

New Insurance Clients

White







Black or African American







Asian







Native Hawaiian or Other Pacific Islander







American Indian or Alaska Native







More than one race







Unreported







Total







*Served clients must have received at least one drug through the ADAP.



  1. Please list the total number of unduplicated clients served by the ADAP who were on the following regimens this reporting quarter:

Please note: The request for this information is not intended as a means to monitor the standard or quality of care being provided through the ADAP. Patients may not be prescribed HAART for a variety of valid reasons, such as HAART is not medically indicated, the patient refused, or the patient may not be ready to begin therapy and deal with the complexities of adherence. All of these reasons relate to the need for an informed client/clinician joint decision.


Regimen

Total Number of Clients

a. Non-HAART (1 or 2 antiretrovirals)



b. HAART regimen (3 or 4 antiretrovirals)



c. More than 4 antiretrovirals




  1. Please indicate the percentage of clients served during this report quarter whose annual household income was less than 200% of the Federal Poverty Level:

________________%


  1. Please indicate which of the following limits applied to your ADAP during the reporting period. For each item that applied, complete the blank with the information requested on that limit. (Check all that apply).


  1. Enrollment cap                                              Max number of enrollees __________


  1. Waiting list                                                    Current number on waiting list _____


  1. Capped expenditure                                     Monetary cap    $______per client


  1. Drug-specific enrollment caps   (ARVs and Hep C meds)         

Medication #1 _____________________Max number of enrollees ______

Medication #2 _____________________Max number of enrollees ______

Medication #3 _____________________Max number of enrollees ______


9. Indicate which of the following developments or changes occurred in your program during this reporting quarter: (Check all that apply)

  • Project budget deficit

  • Change in income eligibility criteria (please specify _______________________________________)

  • Change in medical eligibility criteria (please specify _______________________________________)

  • Added medications to the formulary

  • Deleted medications from the formulary



B. Funding


10. Please enter the funding received during this reporting quarter from each of the following sources (if no funding was received enter “0"):


Funding Source

Amount Received

(to nearest dollar)

a.

Total contributions from Part A EMA(s)/TGAs

$

b.

Total contributions from Part B Base Funding

$

c.

State contributions (other than Ryan White funds and State-required match for supplement)

$

d.

Carry-over of Ryan White funds from previous year

$

e.

Manufacturer Rebates


$

f.

All Insurance Reimbursements, including Medicaid


$


Resources received this quarter (Total of a through f)

$



C. EXPENDITURES


11. For each of the following categories, please enter total expenditures for this quarter:


Expenditure Category

Total Cost

a.

Pharmaceuticals

$

b.

Dispensing and other administrative costs

$

c.

Insurance coverage (including co-pays, deductibles, and premiums)

$

d.

Under the ADAP Flexibility Policy - Adherence

$

e.

Under the ADAP Flexibility Policy - Access

$

f.

Under the ADAP Flexibility Policy - Monitoring

$


Total ADAP expenditures this quarter

$





  1. From the list of ARVs, Hepatitis B and Hepatitis C medications provided below, indicate the medications you purchased and/or dispensed during this reporting quarter. Enter the total cost for medications purchased during the reporting period (Do not include the Dispensing and other administrative fees).

For drugs you dispensed during this quarter, indicated the total number of clients who received this medication at least once during this quarter.




Generic Name

Brand Name

Drug Code

Total Cost

Unduplicated # of Clients


ARVs

A

B

C

D

E

F

amprenavir

Agenerase

d04428



efavirenz, tenofovir disoproxil fumarate, emtricitabine

Atripla

d05847



tipranavir

Aptivus

d05538



lamivudine, zidovudine

Combivir

d04219



indinavir

Crixivan

d03985



emtricitabine

Emtriva

d04884



lamivudine

Epivir

d03858



lamivudine, abacavir sulfate

Epzicom

d05354



saquinavir

Fortovase

d03860



enfuvirtide

Fuzeon

d04853



zalcitabine

Hivid

d00127



saquinavir (as mesylate)

Invirase

d03860



Raltegravir (RGV or MK-0518)

Isentress




ritonavir, lopinavir

Kaletra

d04717



fosamprenavir calcium

Lexiva

d04901



ritonavir

Norvir

d03984



darunavir

Prezista

d05825



delavirdine

Rescriptor

d04119



zidovudine

Retrovir

d00034



atazanavir sulfate

Reyataz

d04882



maraviroc

Selzentry or Celsentri




efavirenz

Sustiva

d04355



abacavir sulfate, lamivudine, zidovudine

Trizivir

d04727



tenofovir disoproxil fumarate, emtricitabine

Truvada

d05352



didanosine

Videx/Videx EC

d00078



nelfinavir

Viracept

d04118



nevirapine

Viramune

d04029



tenofovir disoproxil fumarate

Viread

d04774



stavudine

Zerit

d03773



abacavir sulfate

Ziagen

d04376



Etravirine (TMC-125)







Generic Name

Brand Name

Drug Code

Total Cost

Unduplicated # of Clients

A

B

C

D

E

F


Hepatitis B Treatment Medications:

entecavir

Baraclude

d05525



lamivudine

Epivir-HBV

d03858



interferon alfa-2b

??

d01369



adefovir dipivoxil

Hepsera

d04814



peginterferon alfa-2a

Pegasys

d04821



telbivudine

Tyzeka

??




Hepatitis C Treatment Medications:

interferon alfa-2b

Intron A

d01369



recombinant interferon alfa-2a

Roferon

??



consensus interferon or interferon alfacon-1

Infergen

d04224



peginterferon alfa-2a

Pegasys

d04821



peginterferon alfa-2b

PEG-Intron

d04746



peginterferon alfa-2a + ribavirin

Copegus

d00085



peginterferon alfa-2b and ribavirin

Rebetol

d00085



interferon alfa-2b and ribavirin

Rebetol

d00085



recombinant interferon alfa-2a and ribavirin

Referon

??





  1. Comments or clarifications:

Use this space to provide additional information that you feel it is important to report or to explain how you arrived at data that do not comply with Items 1–11 as described in the Instruction Manual. Please be sure to specify which item(s) you are discussing.



__________________________________________________________________________________________



__________________________________________________________________________________________



__________________________________________________________________________________________



__________________________________________________________________________________________



__________________________________________________________________________________________



STOP HERE if this is the second, third, or fourth quarter data report.


Section 2: Annual Submission

Section 2 (Items 13-21) should be completed only once each year and submitted with the first quarterly report.


A. FUNDING


  1. Please enter the ADAP funding received for this fiscal year from each of the following Ryan White HIV/AIDS program sources:

Funding Source

Amount Received

(to nearest dollar)

a.

ADAP earmark

$

b.

ADAP Supplemental Drug Treatment Grant Award

$

c.

State Match for Supplemental Drug Treatment Award

$


ADAP resources received (total of a through c)

$



  1. ADAP formulary

Using the Excel spreadsheet provided, upload a list of the drugs in your ADAP formulary.


  1. Annual Cost Per Client

For clients enrolled and receiving medications for a full 12-month period, please estimate the annual ADAP cost per client in the previous grant year:


  1. Rebate States and Hybrids:


i. Cost per client before cost-saving strategies: $_______________ per client


ii. Cost per client after cost-saving strategies: $_______________ per client

  1. Direct Purchase States:


i. Annual cost per client: $_______________ per client



B. Eligibility requirements


  1. Please indicate the ADAP eligibility requirements as a percentage of Federal Poverty Level (FPL):

________________ %

  1. Please indicate the frequency of re-certification of client eligibility:

  • Semiannual (every 6 months)

  • Other, please specify _______________________________

  1. Please indicate the clinical eligibility criteria required to enroll in the ADAP in your State/Territory: (Check all that apply.)

  • HIV+

  • CD4 (what is your CD4 count requirement? _____________________________)

  • Viral load (what is your VL count requirement? _____________________________)

  • Other (please specify: _____________________________)





C. Cost Saving Strategies


  1. Please check all that apply to your Drug Pricing Program:

  • Rebate

  • Direct purchase

  • Prime vendor

  • Alternative Method Demonstration Project

  • State does not participate in 340B Drug Pricing Program

  • Other drug discount program (not 340B) (please specify ____________________________)


  1. Please indicate which of the following methods your ADAP uses to coordinate with Medicaid or a State-only Pharmacy Assistance Program: (Check all that apply.)

  • Online interface

  • Dual application

  • Coordinated benefits

  • Retroactive billing

  • Other (please specify ____________________________)



  • We have no coordination with Medicaid or State-only ADAP

  1. Comments or clarifications:

Use this space to provide additional information about data for Items 13-20 that do not comply with what is requested as described in the Instruction Manual.



__________________________________________________________________________________________



__________________________________________________________________________________________



__________________________________________________________________________________________



__________________________________________________________________________________________

ADAP Quarterly Report Page 2

Cover Page: Grantee Contact Information

File Typeapplication/msword
File TitleHealth Resources and Services Administration
AuthorStacy Daft
Last Modified ByHRSA
File Modified2007-12-20
File Created2007-12-20

© 2024 OMB.report | Privacy Policy